Cargando…

PD-1 Blockade in Chronically HIV-1-Infected Humanized Mice Suppresses Viral Loads

An estimated 34 million people are living with HIV worldwide (UNAIDS, 2012), with the number of infected persons rising every year. Increases in HIV prevalence have resulted not only from new infections, but also from increases in the survival of HIV-infected persons produced by effective anti-retro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seung, Edward, Dudek, Timothy E., Allen, Todd M., Freeman, Gordon J., Luster, Andrew D., Tager, Andrew M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3804573/ https://www.ncbi.nlm.nih.gov/pubmed/24204962 http://dx.doi.org/10.1371/journal.pone.0077780

Ejemplares similares

Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade
por: Freeman, Gordon J., et al.
Publicado: (2006)

HIV-infected T cells are migratory vehicles for viral dissemination
por: Murooka, Thomas T., et al.
Publicado: (2012)

Rapid evolution of HIV-1 to functional CD8+ T-cell rResponses in humanized BLT mice
por: Dudek, TE, et al.
Publicado: (2012)

A unique requirement for the leukotriene B(4) receptor BLT1 for neutrophil recruitment in inflammatory arthritis
por: Kim, Nancy D., et al.
Publicado: (2006)

Neutralizing anti-HIV antibodies develop in a humanized mouse model of HIV-1 infection
por: Seung, E, et al.
Publicado: (2012)

The humanized BLT mouse to study HIV transmission
por: Deruaz, M, et al.
Publicado: (2012)

Enhancing SIV-Specific Immunity In Vivo by PD-1 Blockade
por: Velu, Vijayakumar, et al.
Publicado: (2008)

PD-1 blockade reverses viral infection-induced loss of anti-tumor CD8+ T cell responses
por: Huelsmann, Erica, et al.
Publicado: (2013)

Oncolytic virus and PD-1/PD-L1 blockade combination therapy
por: Chen, Chun-Yu, et al.
Publicado: (2018)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
por: Gong, Jun, et al.
Publicado: (2018)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Genetic biomarkers for PD-1/PD-L1 blockade therapy
por: Kataoka, Keisuke, et al.
Publicado: (2016)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

PD-1 blockade enhances chemotherapy toxicity in oesophageal adenocarcinoma
por: Davern, Maria, et al.
Publicado: (2022)

Systemic Anti–PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid
por: Portnow, Jana, et al.
Publicado: (2020)

PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV
por: Davar, Diwakar, et al.
Publicado: (2015)

PD-1 blockade following ART interruption enhances control of pathogenic SIV in rhesus macaques
por: Velu, Vijayakumar, et al.
Publicado: (2022)

PD-1 Blockade in Anaplastic Thyroid Carcinoma
por: Capdevila, Jaume, et al.
Publicado: (2020)

TLR4 signaling improves PD-1 blockade therapy during chronic viral infection
por: Wang, Yidan, et al.
Publicado: (2019)

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
por: Hamanishi, Junzo, et al.
Publicado: (2016)

Drug response to PD-1/PD-L1 blockade: based on biomarkers
por: Chen, Qi, et al.
Publicado: (2018)

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
por: Zhao, Bin, et al.
Publicado: (2020)

Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas
por: Katsuya, Hiroo, et al.
Publicado: (2023)

Application of PD-1 Blockade in Cancer Immunotherapy
por: Wu, Xiaomo, et al.
Publicado: (2019)

Biomarkers of response to PD-1 pathway blockade
por: Li, Hanxiao, et al.
Publicado: (2022)

Epigenetic signature of PD-1+ TCF1+ CD8 T cells that act as resource cells during chronic viral infection and respond to PD-1 blockade
por: Jadhav, Rohit R., et al.
Publicado: (2019)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea, Miruna, et al.
Publicado: (2021)

Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
por: Robbins, Yvette, et al.
Publicado: (2021)

Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
por: Tomlins, Scott A., et al.
Publicado: (2023)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
por: Kamada, Takahiro, et al.
Publicado: (2019)

Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
por: Jiang, Youhai, et al.
Publicado: (2020)

Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
por: Zhuang, Yuan, et al.
Publicado: (2020)

Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade
por: Tian, Tian, et al.
Publicado: (2021)

Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
por: Zhang, Min, et al.
Publicado: (2019)

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
por: Escors, David, et al.
Publicado: (2022)

Recent developments in PD-1/PD-L1 blockade research for gastroesophageal malignancies
por: Chen, Meng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0cbvfr0pgfqffpsd58ncbk9cur